Karyopharm Therapeutics (NASDAQ:KPTI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01, Zacks reports. The firm had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Stock Down 0.5 %

Shares of KPTI stock traded down $0.00 on Thursday, hitting $0.88. The stock had a trading volume of 1,304,245 shares, compared to its average volume of 1,269,637. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The business has a 50 day moving average price of $0.81 and a 200 day moving average price of $0.91. The company has a market cap of $109.99 million, a PE ratio of -0.76 and a beta of 0.16.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).